GlaxoSmithKline: Herpes Zoster trials

The registry lists 44 Herpes Zoster studies with GlaxoSmithKline as lead sponsor. 3 are open to participants now and 34 have results posted.

Phase 1 2Phase 2 9Phase 3 25Phase 4 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular EventsNot yet recruitingNCT07712380Phase 2
• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandRecruitingNCT07502560Phase 4
• A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney TransplantRecruitingNCT04006808Phase 1/2
• A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in IndiaCompletedNCT05219253Phase 3Results posted
• A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster VaccineCompletedNCT05047770Phase 3Results posted
• Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 YearsCompletedNCT04869982Phase 4Results posted
• A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune ResponseCompletedNCT04176939Phase 3Results posted
• Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes ZosterCompletedNCT04091451Phase 3Results posted
• Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix VaccineCompletedNCT03894969Phase 2Results posted
• A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022CompletedNCT03563183Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and OlderCompletedNCT03439657Phase 3Results posted
• Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of AgeCompletedNCT02979639Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and OlderCompletedNCT02735915Phase 3Results posted
• A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older AdultsCompletedNCT02723773Phase 3Results posted
• Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.CompletedNCT02690207Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years EarlierCompletedNCT02581410Phase 3Results posted
• Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in FranceCompletedNCT02487472Results posted
• Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of AgeCompletedNCT02075515Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal TransplantCompletedNCT02058589Phase 3Results posted
• Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and OlderCompletedNCT02052596Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and OlderCompletedNCT02045836Phase 3Results posted
• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and OlderCompletedNCT01954251Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes ZosterCompletedNCT01827839Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving ChemotherapyCompletedNCT01798056Phase 3Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 YearsCompletedNCT01777321Phase 3Results posted
• Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in ItalyCompletedNCT01772160Results posted
• Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood CancersCompletedNCT01767467Phase 3Results posted
• Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or OlderCompletedNCT01751165Phase 3Results posted
• Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173ACompletedNCT01610414Phase 3Results posted
• Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy SubjectsCompletedNCT01295320Phase 2Results posted
• Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and OlderCompletedNCT01165229Phase 3Results posted
• Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected SubjectsCompletedNCT01165203Phase 2Results posted
• Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and OlderCompletedNCT01165177Phase 3Results posted
• Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173ACompletedNCT00920218Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 YearsCompletedNCT00802464Phase 2Results posted
• Month 30 & 42 Extension Studies of CRD-004 Primary StudyCompletedNCT00492648Phase 2Results posted
• Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly SubjectsCompletedNCT00434577Phase 2Results posted
• Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised ConditionsActive, not recruitingNCT05811754
• A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older AdultsActive, not recruitingNCT05371080Phase 3
• A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and AboveCompletedNCT01873365
• Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in SpainCompletedNCT01521286
• Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese AdultsCompletedNCT01086449Phase 1
• VZV PCR Sampling Validation StudyCompletedNCT00501670
• A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune SystemsCompletedNCT00002315Phase 3